FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068704610> ?p ?o ?g. }

• W2068704610 endingPage "3518" @default.
• W2068704610 startingPage "3515" @default.
• W2068704610 abstract "Context: Pegvisomant, a GH receptor antagonist, suppresses serum IGF-I levels into the normal range in more than 95% of patients with acromegaly. Documented side effects in the initial registration studies included headache, injection-site reactions, flu-like syndrome, and reversible elevation of hepatic enzymes. Objective: We report seven patients with acromegaly treated with pegvisomant who developed lipodystrophy at the site of injection (anterior abdominal wall, thigh, buttock, and upper arm). This side effect resulted in discontinuation of pegvisomant in four patients, with subsequent regression of lipohypertrophy. Subjects: Six female and one male patient with acromegaly, aged 24–59 yr, are reported. All patients had undergone prior transsphenoidal surgery, and four received subsequent radiotherapy. Four patients had been treated with maximal doses of somatostatin analogs with partial suppression of IGF-I levels before initiation of pegvisomant therapy. Pegvisomant suppressed IGF-I levels into the normal range in five of seven subjects, before discontinuation of the drug. Two of seven patients received pegvisomant as first-line medical therapy, without prior somatostatin analog treatment, and one received combination therapy with a long-acting somatostatin analog and weekly pegvisomant injections. One patient experienced an erythematous superficial injection-site reaction that responded to application of steroid cream before the onset of lipohypertrophy. Conclusions: We report seven patients with acromegaly who developed lipohypertrophy at the pegvisomant injection site. Pegvisomant was discontinued due to dissatisfaction with lipohypertrophy by four patients. Lipohypertrophy regressed in all patients when the medication was discontinued. Lipohypertrophy recurred when two patients were rechallenged with pegvisomant. Patients receiving pegvisomant should undergo frequent examination of injection sites for lipohypertrophy." @default.
• W2068704610 created "2016-06-24" @default.
• W2068704610 creator A5003838671 @default.
• W2068704610 creator A5009768431 @default.
• W2068704610 creator A5037305490 @default.
• W2068704610 creator A5060580242 @default.
• W2068704610 creator A5066985276 @default.
• W2068704610 creator A5067841207 @default.
• W2068704610 date "2008-09-01" @default.
• W2068704610 modified "2023-10-16" @default.
• W2068704610 title "Lipodystrophy in Patients with Acromegaly Receiving Pegvisomant" @default.
• W2068704610 cites W123434114 @default.
• W2068704610 cites W1966459931 @default.
• W2068704610 cites W1969665744 @default.
• W2068704610 cites W1973741880 @default.
• W2068704610 cites W1974980610 @default.
• W2068704610 cites W1975128137 @default.
• W2068704610 cites W2003334577 @default.
• W2068704610 cites W2018173227 @default.
• W2068704610 cites W2025569597 @default.
• W2068704610 cites W2045942594 @default.
• W2068704610 cites W2060849228 @default.
• W2068704610 cites W2097346238 @default.
• W2068704610 cites W2114461739 @default.
• W2068704610 cites W2121326610 @default.
• W2068704610 cites W2131936635 @default.
• W2068704610 cites W2146407048 @default.
• W2068704610 cites W2147795491 @default.
• W2068704610 cites W2153200944 @default.
• W2068704610 cites W2331609610 @default.
• W2068704610 doi "https://doi.org/10.1210/jc.2008-0833" @default.
• W2068704610 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18611977" @default.
• W2068704610 hasPublicationYear "2008" @default.
• W2068704610 type Work @default.
• W2068704610 sameAs 2068704610 @default.
• W2068704610 citedByCount "62" @default.
• W2068704610 countsByYear W20687046102012 @default.
• W2068704610 countsByYear W20687046102013 @default.
• W2068704610 countsByYear W20687046102014 @default.
• W2068704610 countsByYear W20687046102015 @default.
• W2068704610 countsByYear W20687046102016 @default.
• W2068704610 countsByYear W20687046102017 @default.
• W2068704610 countsByYear W20687046102018 @default.
• W2068704610 countsByYear W20687046102019 @default.
• W2068704610 countsByYear W20687046102020 @default.
• W2068704610 countsByYear W20687046102021 @default.
• W2068704610 countsByYear W20687046102022 @default.
• W2068704610 countsByYear W20687046102023 @default.
• W2068704610 crossrefType "journal-article" @default.
• W2068704610 hasAuthorship W2068704610A5003838671 @default.
• W2068704610 hasAuthorship W2068704610A5009768431 @default.
• W2068704610 hasAuthorship W2068704610A5037305490 @default.
• W2068704610 hasAuthorship W2068704610A5060580242 @default.
• W2068704610 hasAuthorship W2068704610A5066985276 @default.
• W2068704610 hasAuthorship W2068704610A5067841207 @default.
• W2068704610 hasBestOaLocation W20687046101 @default.
• W2068704610 hasConcept C126322002 @default.
• W2068704610 hasConcept C134018914 @default.
• W2068704610 hasConcept C141071460 @default.
• W2068704610 hasConcept C142462285 @default.
• W2068704610 hasConcept C2776297358 @default.
• W2068704610 hasConcept C2777433750 @default.
• W2068704610 hasConcept C2778715236 @default.
• W2068704610 hasConcept C2778886798 @default.
• W2068704610 hasConcept C2779064019 @default.
• W2068704610 hasConcept C2779832395 @default.
• W2068704610 hasConcept C2780941825 @default.
• W2068704610 hasConcept C2781025020 @default.
• W2068704610 hasConcept C2984496839 @default.
• W2068704610 hasConcept C2993143319 @default.
• W2068704610 hasConcept C3013748606 @default.
• W2068704610 hasConcept C512399662 @default.
• W2068704610 hasConcept C71315377 @default.
• W2068704610 hasConcept C71924100 @default.
• W2068704610 hasConceptScore W2068704610C126322002 @default.
• W2068704610 hasConceptScore W2068704610C134018914 @default.
• W2068704610 hasConceptScore W2068704610C141071460 @default.
• W2068704610 hasConceptScore W2068704610C142462285 @default.
• W2068704610 hasConceptScore W2068704610C2776297358 @default.
• W2068704610 hasConceptScore W2068704610C2777433750 @default.
• W2068704610 hasConceptScore W2068704610C2778715236 @default.
• W2068704610 hasConceptScore W2068704610C2778886798 @default.
• W2068704610 hasConceptScore W2068704610C2779064019 @default.
• W2068704610 hasConceptScore W2068704610C2779832395 @default.
• W2068704610 hasConceptScore W2068704610C2780941825 @default.
• W2068704610 hasConceptScore W2068704610C2781025020 @default.
• W2068704610 hasConceptScore W2068704610C2984496839 @default.
• W2068704610 hasConceptScore W2068704610C2993143319 @default.
• W2068704610 hasConceptScore W2068704610C3013748606 @default.
• W2068704610 hasConceptScore W2068704610C512399662 @default.
• W2068704610 hasConceptScore W2068704610C71315377 @default.
• W2068704610 hasConceptScore W2068704610C71924100 @default.
• W2068704610 hasIssue "9" @default.
• W2068704610 hasLocation W20687046101 @default.
• W2068704610 hasLocation W20687046102 @default.
• W2068704610 hasOpenAccess W2068704610 @default.
• W2068704610 hasPrimaryLocation W20687046101 @default.
• W2068704610 hasRelatedWork W1982345662 @default.

• next